SCHEMBL30734239

SCHEMBL30734239

Nc1cc(-c2ccc3ncnc(N4CCC(c5ccc(F)cc5F)CC4)c3c2)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.43
CHRM4 P08173 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.42
CYP1A2 P05177 10/20 0.41
CYP3A4 P08684 10/20 0.41
CLK4 Q9HAZ1 8/20 0.41
ALDH1A1 P00352 7/20 0.41
HIF1A Q16665 4/20 0.41
LMNA P02545 4/20 0.41
MAPK1 P28482 3/20 0.41
CYP2D6 P10635 5/20 0.41
USP2 O75604 4/20 0.41
HSD17B10 Q99714 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 2/20 0.40
ALOX15 P16050 1/20 0.40
CYP2C9 P11712 1/20 0.40
MAP4K4 O95819 2/20 0.40
PI4KA P42356 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30734162 0.89 IRAK4 (0.45) IRAK4CYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL30734212 0.84 HTT (0.49) HTTIRAK4CYP1A2CYP3A4CLK4
SCHEMBL30734218 0.81 CYP3A4 (0.46) IRAK4CYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL30734136 0.81 HTT (0.55) HTTCHRM4ALDH1A1LMNAMAPK1
SCHEMBL30734233 0.81 ACHE (0.55) HTTIRAK4CYP1A2CYP3A4CLK4
SCHEMBL31745229 0.78 CYP1A2 (0.52) HTTIRAK4CYP1A2CYP3A4CLK4
SCHEMBL30734221 0.77 LMNA (0.51) HTTCYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL30734134 0.77 ACHE (0.58) HTTCYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL30734169 0.75 CYP3A4 (0.54) CYP1A2CYP3A4CLK4ALDH1A1HIF1A
SCHEMBL30734231 0.74 CYP3A4 (0.52) IRAK4CYP1A2CYP3A4CLK4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 US disclosed
EP-4543888-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF Arizona Board of Regents on behalf of The University of Arizona (US) 2025-04-30 EP disclosed
WO-2023250083-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 HTT 713/4885CHRM4 3276/4885IRAK4 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.